Optimi Health Corp. is advancing the largest controlled psilocybin trial for MDD documented in the available evidence — up to 200 participants across multiple Canadian sites, Health Canada-authorized, targeting dosing completion by end of 2027 — but the announcement's strategic weight is undermined by what it does not disclose. The strongest mechanistically matched evidence available is a randomized Phase 2 RCT (synthetic psilocybin 25 mg vs. niacin, n=104, 11 US sites) that demonstrated MADRS mean differences of −12.3 at day 43 and −12.0 at day 8 (both P <.001) with no serious treatment-emergent adverse events — this is the primary efficacy anchor for the mechanism, and it passed both the mechanistic-fit test (5-HT2A agonism, single-dose, psychological support, MDD population) and the contextual-fit test. A single-arm open-label pilot in 15 Veterans with severe treatment-resistant depression (25 mg, MADRS primary) showed 60% response and 53% remission at Week 3, declining to 40% response and 30% remission at Month 12 — a durability attrition signal that is now a field-wide expectation regulators will scrutinize. [1] A meta-analysis across 12 controlled trials (n=733) confirmed a large overall effect size (Hedges g = −0.84; P <.001) for psychedelic-assisted therapy in depressive symptoms, with more preparation therapy hours significantly predicting greater symptom reduction (β = −0.13; P = .04). No regulatory approval or HTA decision for psilocybin in MDD exists in the available evidence — no precedent clears the mechanistic-fit bar at the approval level, making this a genuinely novel regulatory pathway. The critical unresolved risks are three: Health Canada has no documented precedent for naturally derived (vs. synthetic) psilocybin from a chemistry, manufacturing, and controls standpoint; the press release specifies neither comparator arm design, primary endpoint instrument, MDD population severity criteria, nor post-dose follow-up duration; and 75% of prior psilocybin trials carried high risk of bias due to ineffective blinding, a methodological weakness that a 2026 commentary identifies as requiring explicit Lessebo-effect management in control arms. No payer or HTA cost-effectiveness data for psilocybin in MDD exist in the available evidence. The sharpest risk: a single-arm Phase 2 without long-term follow-up will not meet the evidentiary bar that HTA bodies — as illustrated by NICE's scrutiny of trial duration and endpoint definitions in depression indications — are increasingly applying to novel psychiatric treatments. [2]
A randomized Phase 2 RCT (synthetic psilocybin vs. niacin, n=104) demonstrated MADRS mean differences of −12.3 at day 43 (P <.001), but Optimi's trial uses naturally derived psilocybin with no documented regulatory equivalence, and key design parameters — comparator arm, endpoint, follow-up duration — remain undisclosed.
| Indication | Major Depressive Disorder |
| Drug | Psilocybin |
| Company | Optimi Health Corp. |
| Trial Phase | Phase 2 |
| Category | Clinical Trial Event |
| Sub Category | Trial Initiation / First Patient In (FPI) |
| Therapeutic Area | Neuroscience |
| Regulatory Body | Health Canada |
| Patient Population Size | Up to 200 participants |
| Primary Efficacy Endpoint | Change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline |
| Trial Location | Canada |
| Trial Initiation | First half of 2027 |
| Dosing Completion | End of 2027 |
| Drug Origin | Naturally derived |
| Dosage | Single supervised dose |
| Manufacturing Standard | GMP-compliant |
| Funding | Current cash on hand |
| CEO | Dane Stevens |
| Press Release Date | September 10, 2026 |
Optimi Health to Launch Phase 2 Psilocybin Trial for MDD
Optimi Health Corp. announced plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for Major Depressive Disorder (MDD). The Health Canada-authorized trial will enroll up to 200 participants across multiple sites in Canada, assessing the safety and efficacy of a single supervised dose of natural psilocybin. Dosing is expected to be completed by the end of 2027, with the trial planned to start in the first half of 2027. This represents Optimi's largest clinical commitment to date, utilizing its own naturally derived psilocybin.
- Optimi Health's Phase 2 clinical trial for Major Depressive Disorder (MDD) is authorized by Health Canada and will be a multisite study across Canada, enrolling up to 200 participants. It aims to evaluate the safety and efficacy of a single supervised dose of natural psilocybin, making it one of the largest studies of naturally derived psilocybin to date.
- The trial is planned to commence in the first half of 2027, with dosing anticipated to conclude by the end of 2027. The primary efficacy endpoint is the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline, a widely recognized measure for depressive symptom severity in trials of this kind.
- This Phase 2 trial marks Optimi's largest clinical commitment, broadening its strategy to include clinical drug development. The company will supply its own GMP-manufactured psilocybin and will exclusively own the trial results, funding the study with current cash on hand, leveraging its existing Drug Establishment Licence in Canada.
Addressing Persistent Challenges in Major Depressive Disorder Treatment
Despite decades of pharmacological development, treatment of Major Depressive Disorder (MDD) remains constrained by fundamental limitations in efficacy, tolerability, and treatment selection. These challenges drive significant unmet need, particularly for patients who fail to respond to first-line therapies.
Trial-and-error treatment selection: Response to available antidepressants is varied and treatment selection remains largely guided by trial-and-error. In a cohort of 73,601 patients, machine learning-driven data-driven selection of antidepressant type yielded only a small improvement over current practice, and prediction of treatment outcome was mostly driven by initial PHQ-9 score (AUC 0.61 as a sole predictor), underscoring the absence of robust, clinically actionable predictive tools.
High rates of treatment resistance: Approximately 30% of patients treated for MDD develop treatment-resistant depression (TRD). The STAR*D study demonstrated that remission rates decline progressively with each antidepressant failure — 37%, 31%, 14%, and 13%, respectively — leaving a substantial proportion of patients without adequate symptom control after multiple treatment attempts.
Delayed onset of action with monoaminergic agents: Current first-line antidepressants of the SSRI and SNRI class have a delayed onset of action, which is a recognised limitation. This delay is particularly consequential for acutely depressed and suicidal patients, who often require prolonged inpatient stabilisation while awaiting therapeutic effect.
Tolerability and discontinuation burden: Adverse event profiles continue to limit adherence. Withdrawal rates due to treatment-emergent adverse events (TEAEs) with active comparators such as venlafaxine XR reached 14.2% and duloxetine 8.8% in short-term trials. Common TEAEs across agents include nausea, sexual dysfunction, and weight changes, all of which contribute to premature discontinuation and suboptimal long-term outcomes.
Lack of validated biomarkers for treatment response: Objective biomarkers capable of predicting and monitoring therapeutic response are urgently needed to enable personalised interventions and reduce patient exposure to ineffective treatments. Emerging approaches — including mass spectrometry-based multi-omics platforms and plasma immune markers such as kynurenic acid for ECT response prediction — remain investigational and have not yet been integrated into routine clinical practice.
Augmentation versus switching uncertainty: For patients failing initial antidepressant treatment, neither augmentation nor switching strategies have demonstrated a clear superiority in remission rates, response rates, time to remission, or quality of life, as shown in a retrospective analysis of STAR*D participants (N = 1,292). Post hoc analyses suggested augmentation may benefit patients tolerating 12 or more weeks of initial treatment with a partial response, but no definitive guidance exists for the broader population.
Optimi Health's Phase 2 Psilocybin Trial Design for MDD
Several pivotal trials across pharmacological classes have evaluated antidepressant agents in MDD, employing randomized, double-blind, placebo-controlled designs with standardized depression rating scales as primary endpoints. The studies span acute treatment phases (6–8 weeks) through long-term maintenance paradigms, with patient populations ranging from first-line treatment to treatment-resistant depression (TRD).
| Study / Agent | Design | Duration | Population | Primary Endpoint | Key Secondary Endpoints | Notable Findings |
|---|---|---|---|---|---|---|
| Esketamine nasal spray (SYNAPSE, SUSTAIN-1, SUSTAIN-2) | Phase 2/3 registration studies | Induction (4 weeks, twice-weekly) followed by weekly then weekly/every-other-week maintenance | Adult TRD patients | Maintenance of antidepressant effect | Not reported | Maintenance of efficacy established with intermittent dosing regimen; antidepressant effect persisted in most patients during long-term maintenance |
| TC-5214 (dexmecamylamine) — Studies 004 & 005 | 8-week open-label SSRI/SNRI run-in followed by 8-week randomized, double-blind, placebo-controlled adjunct phase | 16 weeks total | MDD patients with inadequate response to prior antidepressant therapy; Study 004: n=640; Study 005: n=696 | Change in MADRS total score from Week 8 (randomisation) to Week 16 (treatment end) | MADRS response and remission rates; SDS and HAM-D-17-item score changes | No statistically significant improvements in MADRS total score or any secondary endpoints versus placebo in either study |
| Desvenlafaxine succinate (NCT00063206) | 8-week, multicenter, randomized, double-blind, placebo-controlled | 8 weeks | Adult outpatients aged 18–75 years with primary MDD diagnosis (DSM-IV); n=247 randomized, n=234 intent-to-treat | HAM-D₁₇ score at final on-therapy evaluation | CGI-I (key secondary); MADRS; CGI-S; VAS-PI overall and subcomponent scores; HAM-D₁₇ response and remission rates | No significant difference on HAM-D₁₇ or CGI-I; significantly greater improvement in MADRS (p=.047) and VAS-PI overall pain (p=.008), back pain (p=.006), and arm/leg/joint pain (p<.001) |
| Edivoxetine adjunct to SSRI — Pooled safety analysis | Pooled post hoc analysis of integrated safety database | Not reported | MDD patients; edivoxetine n=1260; placebo n=806 | Safety and tolerability (TEAEs, BP, pulse, ECG, laboratory measures) | Discontinuation rates | Study completion 85.2% (edivoxetine) vs. 84.5% (placebo); most common TEAEs (≥5%): hyperhidrosis, nausea, tachycardia; significant increases in SBP (2.7 vs. 0.5 mmHg), DBP (4.1 vs. 0.8 mmHg), pulse (8.8 vs. −1.3 bpm) |
| Aripiprazole adjunct to ADT — Studies CN138-139 & CN138-163 (pooled) | 8-week prospective ADT run-in followed by 6-week randomized, double-blind adjunctive phase; pooled post hoc analysis | 14 weeks total | MDD outpatients (DSM-IV-TR); aripiprazole n=371; placebo n=366 | Incidence of TEAEs; weight, ECG, and laboratory measurements | Time course, severity, resolution, and predictors of TEAEs | Common TEAEs (≥5%, ≥2× placebo rate): akathisia (25%), restlessness (12%), insomnia (8%), fatigue (8%), blurred vision (6%), constipation (5%); mean weight gain 1.73 kg vs. 0.38 kg (p<.001) |
| Vortioxetine vs. Venlafaxine XR (SOLUTION; NCT01571453) | Randomized, double-blind, 8-week, fixed-dose, non-inferiority | 8 weeks | Adults aged 18–65 with recurrent MDD, MADRS ≥26, CGI-S ≥4; vortioxetine n=209, venlafaxine XR n=215 | Change from baseline to Week 8 in MADRS total score (ANCOVA, FAS, LOCF); non-inferiority margin +2.5 points | MADRS response and remission rates; HAM-A; CGI; SDS; Q-LES-Q | Non-inferiority established (difference −1.2 MADRS points, 95% CI: −3.0 to 0.6); remission rates (MADRS ≤10): 43.1% (vortioxetine) vs. 41.4% (venlafaxine XR); fewer withdrawals with vortioxetine (18.0% vs. 27.4%) |
| Vortioxetine — Pooled safety analysis (11 RCTs + 5 OLE studies) | Pooled analysis of 11 randomized, double-blind, placebo-controlled short-term studies (6/8 weeks); 5 open-label extension studies (≤52 weeks) | Acute: 6–8 weeks; long-term: ≤52 weeks | MDD adults; placebo n=1817; vortioxetine 5–20 mg/day n=3018; venlafaxine XR 225 mg/day n=113; duloxetine 60 mg/day n=753 | Nature, incidence, and severity of TEAEs; discontinuation symptoms (DESS checklist) | Laboratory parameters, body weight, heart rate, blood pressure, ECG (QTcF) | Withdrawal due to TEAEs: vortioxetine 4.5–7.8% vs. placebo 3.6%, venlafaxine XR 14.2%, duloxetine 8.8%; common TEAEs: nausea (20.9–31.2%), vomiting (2.9–6.5%); no clinically relevant effect on weight, ECG, or QTcF |
| rTMS vs. sham — Systematic review and meta-analysis | Systematic review and meta-analysis of RCTs; random-effects model | Inception to March 15, 2017 | MDD patients with acute depressive episodes; 61 studies (N=1328); mean age 47 years; 57% female | Placebo (sham) effect size (Hedges's g) using baseline and endpoint depressive symptom scores | Moderators: publication year, active group depression improvement, treatment-resistant depression level, gender, age, stimulator type | Placebo response: g=0.8 (95% CI=0.65–0.95, p<0.01); inversely associated with higher levels of treatment-resistant depression |
| Antidepressant discontinuation — Systematic review and meta-analysis (37 RCTs) | Systematic review and meta-analysis of double-blind, randomized, placebo-controlled maintenance-phase RCTs | Inception to Feb 20, 2021 | Unipolar depression patients; 37 RCTs meeting inclusion criteria (screened from 5351 records) | Relapse rate (odds ratios pooled via random-effects model) | Meta-regression on open-label treatment duration, double-blind phase duration, age, medication type, history of recurrence | Active medication superior to placebo for relapse prevention (OR=0.37; 95% CI, 0.32–0.42); no relationship between treatment duration and effect sizes; relapse rate in placebo group decreased over time |
The Emerging Psychedelic Landscape for Major Depressive Disorder
Several serotonergic psychedelics share psilocybin's primary mechanism of action — serotonin 2A (5-HT2A) receptor agonism — and are under active clinical investigation for depression and related treatment-resistant conditions. The compounds with the most advanced clinical programmes are LSD, DMT, and 5-MeO-DMT, each being evaluated across Phase II trials with structured psychedelic-assisted therapy frameworks.
| Drug | Shared MoA | Indication(s) | Trial Stage & Volume | Intervention Model Notes |
|---|---|---|---|---|
| LSD (lysergic acid diethylamide) | 5-HT2A receptor agonist | Anxiety, depression, existential distress (life-threatening disease) | Included in RCTs reviewed in 2024 Cochrane analysis (6 studies, 149 participants) | Psychedelic-assisted therapy: substance-induced psychedelic experience preceded by preparatory therapeutic sessions and followed by integrative therapeutic sessions; outpatient settings (USA, Switzerland) |
| DMT (N,N-dimethyltryptamine) | Primary 5-HT2A receptor partial agonist | Major depressive disorder (MDD) | Two Phase II studies with DMT fumarate for MDD | Administered via alternative routes (inhalation, intranasal, or intravenous delivery) in monotherapy; broader PAP framework applies |
| 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) | Higher affinity for 5-HT1A vs. 5-HT2A, though 5-HT2A engagement is noted; fosters neuroplasticity and reorganisation of brain networks | Treatment-resistant depression (TRD) | Four Phase II studies | Administered via alternative routes (inhalation, intranasal, or intravenous delivery) in monotherapy |
| MDMA (3,4-methylenedioxymethamphetamine) | Not a classical serotonergic psychedelic; distinct MoA | Anxiety, depression in life-threatening disease | 1 RCT, 18 participants (very low certainty evidence) | Same preparatory and integrative session structure as classical psychedelic trials; outpatient setting |
Note on MDMA: Although included in psychedelic-assisted therapy trials for the same patient populations, MDMA does not share the classical 5-HT2A agonist mechanism of action as psilocybin and is therefore not a mechanistic comparator. Evidence for its effect on anxiety and depression in this population is rated as very low certainty.
Across all classical psychedelic compounds (psilocybin, LSD, DMT, 5-MeO-DMT), the intervention model consistently involves psychotherapeutic support structured around three phases — preparation, drug administration (dosing), and integration — with sessions conducted in outpatient settings. The knowledge base does not have sufficient information on this aspect regarding the specific session counts, manual details, or provider eligibility criteria for the DMT and 5-MeO-DMT Phase II trial protocols.
Beyond MDD: Psilocybin's Expanding Therapeutic Horizons
Psilocybin's clinical development extends well beyond major depressive disorder, with trials spanning addiction, anxiety, and other psychiatric conditions. Across published studies, psilocybin-assisted psychotherapy (PAP) — combining preparatory, supported dosing, and integration sessions — serves as the predominant intervention model, though protocols vary considerably in session number, duration, and therapeutic framework.
| Indication | Key Findings | Intervention Model | Doses Used |
|---|---|---|---|
| Alcohol Use Disorder (AUD) | Significantly fewer heavy drinking days; increased abstinence rates; neuroimaging data indicating normalization of brain activity; in one RCT (n=95), percentage of heavy drinking days was significantly lower for psilocybin vs. placebo (mean difference 13.9, 95% CI = 3.0–24.7, p = 0.01) | Psilocybin-assisted psychotherapy (PAP): preparatory, supported dosing, and integration sessions | 6–40 mg |
| Tobacco Use Disorder (TUD) | High smoking abstinence rates; 7-day point prevalence of smoking abstinence at 26 weeks was 80% (12/15) and at 52 weeks 67% (10/15); mystical experiences predicting long-term outcomes | PAP: preparatory, supported dosing, and integration sessions | Microdosing to 20–40 mg/70 kg |
| Opioid Use Disorder | Potential in reducing opioid dependence; findings mixed | PAP where reported | Not reported |
| Nicotine Use Disorder | Potential reduction in nicotine use; findings mixed | PAP where reported | Not reported |
| Cocaine Use Disorder | Findings mixed | PAP where reported | Not reported |
| Obsessive-Compulsive Disorder (OCD) | Evidence identified in clinical studies | Substance-assisted psychotherapy | Not reported |
| Anxiety and Depression in Life-Threatening Illness | Encouraging efficacy in reducing anxiety symptoms; therapeutic effects lasted weeks; no severe adverse events reported | PAP: preparatory, supported dosing, and integration sessions | Not reported |
| Social Anxiety Disorder | Evidence of symptom reduction, increased self-perception and social function; no severe adverse events reported | Psychedelic-assisted trial | Not reported |
| Post-Traumatic Stress Disorder (PTSD) | Identified as an indication with promising evidence | Substance-assisted psychotherapy | Not reported |
Natural Psilocybin: Optimi's Bold Bet in the MDD Landscape
The landscape of mental health treatment is on the cusp of a significant transformation, with psilocybin-assisted therapy emerging as a compelling new frontier for Major Depressive Disorder (MDD). Optimi Health Corp.'s announcement to initiate a multisite Phase 2 clinical trial for MDD, utilizing its own naturally derived psilocybin, underscores this shift. This move is particularly noteworthy as it leverages a natural product, aligning with a broader scientific re-exploration of plant-based compounds for drug discovery, potentially offering a distinct profile compared to synthetic counterparts.
Existing clinical literature provides a robust foundation for this optimism. Studies indicate that a single dose of psilocybin, administered with psychological support, can lead to rapid and sustained reductions in depressive symptoms and functional disability. This effect has been observed even in severe treatment-resistant depression, where current pharmacological options often fall short. Initial findings suggest psilocybin may offer a more effective pathway to remission for some patients than traditional antidepressants, presenting a significant opportunity to address a substantial unmet medical need.
However, the path forward is not without its considerations. While the immediate safety profile in controlled settings appears favorable, with common adverse events like headache and nausea typically transient, some studies have reported a higher rate of overall and severe adverse events compared to placebo. Furthermore, the long-term durability of psilocybin's antidepressant effects remains an area requiring further investigation, as some evidence suggests a waning of benefits after 6-9 months. Many promising early studies have been limited by small sample sizes or open-label designs, emphasizing the critical need for larger, well-controlled trials like Optimi's Phase 2 to confirm efficacy, safety, and the optimal therapeutic framework. Optimi's substantial commitment positions them as a key player, but the success of this trial will be pivotal in validating natural psilocybin's role and shaping future treatment paradigms for MDD.
Frequently Asked Questions
References
- [1] Bilu Y, El-Hay T et al.. Data driven versus standard practice policies for personalized antidepressant treatment: a retrospective cohort study of electronic health records. BMC psychiatry. 2026 Jan 3. 41485075
- [2] Majić T, Jungaberle H et al.. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. Fortschritte der Neurologie-Psychiatrie. 2017 Jul. 28768346
- [3] Evans VD, Arenas A et al.. Psychedelic Therapy: A Primer for Primary Care Clinicians-Ketamine. American journal of therapeutics. 2024 Mar-Apr 01. 38518272
- [4] Lappan SN, Davis SD. Suggested Guidelines for Applying a Systemic Lens to Psychedelic-Assisted Psychotherapy. Psychedelic medicine (New Rochelle, N.Y.). 2026 Jun. 42131862
- [5] Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS drugs. 2010 Jun. 20192279
- [6] Singh JB, Fedgchin M et al.. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants. Advances in pharmacology (San Diego, Calif.). 2020. 32616208
- [7] Meshkat S, Malik G et al.. Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review. Neuroscience and biobehavioral reviews. 2025 Jun. 40245969
- [8] Gründer G, Jungaberle H. The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. Pharmacopsychiatry. 2021 Jul. 33979868
- [9] Baldwin DS, Chrones L et al.. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of psychopharmacology (Oxford, England). 2016 Mar. 26864543
- [10] Van de Velde N, Kappen M et al.. Cognitive remediation following electroconvulsive therapy in patients with treatment resistant depression: randomized controlled trail of an intervention for relapse prevention - study protocol. BMC psychiatry. 2020 Sep 16. 32938410
- [11] Gaynes BN, Dusetzina SB et al.. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. Journal of clinical psychopharmacology. 2012 Feb. 22198447
- [12] Hovmand OR, Poulsen ED et al.. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review. Journal of psychopharmacology (Oxford, England). 2023 Jul. 37403379
- [13] van der Meer PB, Fuentes JJ et al.. Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in psychiatry. 2023. 36846225
- [14] Andersen KAA, Carhart-Harris R et al.. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta psychiatrica Scandinavica. 2021 Feb. 33125716
- [15] Kowalczyk E, Borysowski J et al.. Placebo-controlled randomized clinical trials of antidepressants for major depressive disorder: Analysis of ClinicalTrials.gov, 2008-2022. Psychiatry research. 2024 Mar. 38245978
- [16] Klein EW, Hunt JS et al.. Depression screening interfaced with an electronic health record: a feasibility study in a primary care clinic using optical mark reader technology. Primary care companion to the Journal of clinical psychiatry. 2006. 17245452
- [17] Aday JS, Horton D et al.. Psychedelic-assisted psychotherapy: where is the psychotherapy research?. Psychopharmacology. 2024 Aug. 38782821
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
